CD177 and cancer: We reviewed RAGE and its ligands, as well as various inhibitors that can provide a platform for researchers and clinicians to develop a novel strategy for tackling numerous types of cancers, considering that RAGE is a cell surface receptor known to interact with a wide range of ligands.